GlassScriptPhysician profile
Matthew R Voss
NPI 1104830579
$33,172.40
in general payments reported to CMS, 2019-2025
24 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $177 · 2021: $166 · 2022: $681 · 2023: $345 · 2024: $3,711 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Consulting Fee: $4,744 · Travel and Lodging: $4,249 · Food and Beverage: $3,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,831.26 |
| Consulting Fee | $4,743.75 |
| Travel and Lodging | $4,249.37 |
| Food and Beverage | $3,227.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $28,536.67 | 2021-2025 | Symplicity G3, Corevalve Evolut R, Micra |
| Edwards Lifesciences Corporation | $2,162.81 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $1,041.37 | 2019-2024 | Synergy |
| Chiesi USA, INC. | $265.84 | 2019-2024 | Kengreal |
| Abiomed | $252.95 | 2022-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $240.43 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $127.17 | 2019 | |
| Shockwave Medical, INC | $123.62 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $105.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $62.21 | 2019 | |
| Novo Nordisk INC | $41.20 | 2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.74 | 2019-2024 | Jardiance |
| Cardiva Medical, INC. | $27.07 | 2024 | Optowire |
| Teleflex LLC | $26.96 | 2019 | |
| Terumo Medical Corporation | $19.58 | 2023 | Optitorque, Navicross |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 200 LLC | $19.07 | 2021 | |
| Biotronik INC. | $18.11 | 2025 | |
| Atricure, INC. | $16.48 | 2020 | |
| Akcea Therapeutics, INC. | $16.29 | 2019 | |
| Philips North America LLC | $15.65 | 2024 | (Cm9) Amb Mon & Diag Und |
| E.R. Squibb & Sons, L.L.C. | $13.34 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Voss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.